84.85
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$89.55
Aprire:
$89.71
Volume 24 ore:
1.05M
Relative Volume:
0.60
Capitalizzazione di mercato:
$7.04B
Reddito:
$1.73B
Utile/perdita netta:
$682.64M
Rapporto P/E:
10.97
EPS:
7.7364
Flusso di cassa netto:
$411.18M
1 W Prestazione:
+1.85%
1M Prestazione:
+15.68%
6M Prestazione:
+9.44%
1 anno Prestazione:
+71.34%
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
PTCT
Ptc Therapeutics Inc
|
84.85 | 7.04B | 1.73B | 682.64M | 411.18M | 7.7364 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Outperform |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-12-01 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-06-17 | Iniziato | Truist | Buy |
| 2025-05-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-07 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-11 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
PTC Therapeutics (PTCT) Q3 2024 earnings summary - Quartr
PTC Therapeutics (PTCT) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
PTC Therapeutics (PTCT) Q2 2024 earnings summary - Quartr
PTC Therapeutics (PTCT) Stock May Be Fully Priced After Rare Disease Data - Yahoo Finance
Reasons why investors should consider betting on PTC stock now - MSN
Is PTC Therapeutics (PTCT) A Bargain Following Its Russell 2000 Defensive Index Additions? - Yahoo Finance UK
PTC Therapeutics Drops 5.5% Amid Sector-Wide Selling - AlphaStreet
Reasons Why Investors Should Consider Betting on PTC Stock Now - Yahoo Finance
PTCT (NASDAQ: PTCT) affiliate sale notice — Form 144 - Stock Titan
Form 144 PTC THERAPEUTICS For: 9 July By Investing.com - Investing.com Australia
Stocks Look Shaky, But This Sector is Booming (Biotech) - Yahoo Finance
[144] PTC THERAPEUTICS, INC. SEC Filing - Stock Titan
Responsive Playbooks and the PTCT Inflection - Stock Traders Daily
Ptc therapeutics tech ops chief sells $4.1m in common stock By Investing.com - Investing.com India
Form 4 PTC Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
PTC Therapeutics Inc. (PTCT) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $120 - Moomoo
PTC Therapeutics(PTCT.US) Officer Sells US$4.09 Million in Common Stock - Moomoo
Ptc therapeutics tech ops chief sells $4.1m in common stock - Investing.com
PTC Therapeutics’ Mark Boulding, exec VP, sells $432,117 in stock - Investing.com
PTC Therapeutics’ Mark Boulding, exec VP, sells $432,117 in stock By Investing.com - Investing.com Canada
PTC Therapeutics (PTCT) officer sells shares after exercising options - Stock Titan
PTC Therapeutics (PTCT) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance Australia
PTC Therapeutics Jumps 5.1% Amid Sector-Wide Rally - AlphaStreet
Form 144 PTC THERAPEUTICS For: 7 July By Investing.com - Investing.com Nigeria
PTCT (NASDAQ: PTCT) — 24,613 shares reported for sale after option exercise - Stock Titan
PTCT Maintains Rating by RBC Capital -- Price Target Raised to $85 - GuruFocus
Ptc Therapeutics stock hits all-time high of 87.56 USD - Investing.com
Ptc Therapeutics stock hits all-time high of 87.56 USD By Investing.com - Investing.com Canada
PTC Therapeutics weighs strategy amid rare disease focus - Ad-hoc-news.de
RBC Capital Adjusts PTC Therapeutics Price Target to $85 From $82, Maintains Sector Perform Rating - Moomoo
Does Triple Russell 2000 Defensive Index Inclusion Reframe PTC Therapeutics’ Risk Profile And Rare-Disease Story (PTCT)? - simplywall.st
Form 144 PTC THERAPEUTICS For: 6 July By Investing.com - Investing.com South Africa
PTCT (NASDAQ) insider sales: 50,162 shares in June; option exercise 07/06/2026 - Stock Titan
PTCT (NASDAQ) affiliate plans option exercise; director sold 10,522 shares - Stock Titan
All eyes on PTC Therapeutics earnings after brutal Q4 miss - Investing.com
Enterprise value to EBIT forward of PTC Therapeutics, Inc. – NASDAQ:PTCT - TradingView
PTC Therapeutics updates investors on rare disease pipeline as Nasdaq-listed biotech advances progra - AD HOC NEWS
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data - TradingView
PTC Therapeutics Inc (PTCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ptc therapeutics chief technical ops officer sells $693k in stock By Investing.com - Investing.com Australia
Ptc therapeutics chief technical ops officer sells $693k in stock - Investing.com Australia
Form 4 PTC Therapeutics Inc For: 30 June By Investing.com - Investing.com South Africa
Enterprise value to EBITDA forward of PTC Therapeutics, Inc. – NASDAQ:PTCT - TradingView
Price to sales forward of PTC Therapeutics, Inc. – NASDAQ:PTCT - TradingView
Enterprise value to revenue forward of PTC Therapeutics, Inc. – NASDAQ:PTCT - TradingView
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to Russell 2000 Value-Defensive Index - marketscreener.com
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Price to earnings forward of PTC Therapeutics, Inc. – HAM:BH3 - TradingView
Price to earnings forward of PTC Therapeutics, Inc. – FWB:BH3 - TradingView
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to Russell 2000 Defensive Index - marketscreener.com
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):